Plant

| Peer-Reviewed |

Asparagus racemosus Linn. Potentiates the Hypolipidemic and Hepatoprotective Activity of Fenofibrate in Alloxan-Induced Diabetic Rats

Received: 12 July 2016    Accepted: 18 September 2016    Published: 18 October 2016
Views:       Downloads:

Share This Article

Abstract

Diabetes mellitus is strongly connected with changes in lipid profile and also can cause damage of several organs like liver over a long period of time. The purpose of this study was designed to evaluate the hypolipidemic and hepatoprotective effects of ethanolic root extracts of Asparagus racemosus (EEAR) Linn. alone and in combination with a lipid lowering agent (fenofibrate) in alloxan-induced diabetic rats. Diabetes was induced in male Wister albino rats by the administration of single intra-peritoneal injection of alloxan monohydrate (120 mg/kg b.w.). Two different doses of EEAR (200 and 400 mg/kg b.w.) alone, fenofibrate (30 mg/kg b.w.) and a combination of EEAR (200 mg/kg b.w.) with fenofibrate (30 mg/kg b.w.) were administered orally for the period of 14 days. After the treatment period, hypolipidemic and hepatoprotective effects were determined by examining serum biochemical markers including total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), very low density lipoprotein (VLDL), high density lipoprotein (HDL), serum glutamate oxaloacetate transaminases (SGOT), serum glutamate pyruvate transaminases (SGPT) and total protein (TP) with the aid of commercially available kits. The survival rate, body weight and organ weight were also measured. The ingestion of EEAR considerably (p < 0.05, p < 0.01, p < 0.001; p < 0.05, p < 0.01) modified the activity of TC, TG, LDL, VLDL and HDL cholesterol levels when compared to the disease control and fenofibrate treated rats. The administration of combination therapy significantly (p < 0.001; p < 0.001) improved the activity of TC, TG, LDL, VLDL and HDL levels when compared to that of disease control and fenofibrate treated rats. The rats treated with EEAR markedly (p < 0.05, p < 0.01, p < 0.001; p < 0.05) reduced the level of SGOT, SGPT and TP as compared to the disease control and fenofibrate treated rats. The suggested combination therapy significantly (p < 0.001; p < 0.001) decreased the level of SGOT, SGPT and TP when compared to that of disease control and fenofibrate treated rats indicated amelioration in liver dysfunctions. The maximum survival rate was 100% found in combination therapy. During treatment period, it was observed that the considerable (p < 0.01, p < 0.001; p < 0.05, p < 0.01, p < 0.001) changes in the body weight were found in the EEAR treated rats and combination therapy on 10th and 14th day as compared to that of disease control and fenofibrate treated rats. In case of organs weight, the weight of the liver and weight of the pancreas were significantly (p < 0.001; p < 0.05, p < 0.01, p < 0.001) decreased in the rats treated with highest dose of EEAR (Alx+ EEAR 400) and combination therapy when compared to the disease control and fenofibrate treated rats. The current study demonstrates that combination therapy of EEAR and fenofibrate was more effective than that of monotherapy in controlling diabetes mellitus associated with cardiovascular diseases and hepatic dysfunction in alloxan-induced diabetic rats.

DOI 10.11648/j.plant.s.2017050501.11
Published in Plant (Volume 5, Issue 5-1, October 2017)

This article belongs to the Special Issue Phytotherapy

Page(s) 1-12
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Diabetes Mellitus, Asparagus racemosus, Hypolipidemic Activity, Hepatoprotective Activity, Fenofibrate, Combination Therapy

References
[1] Saha S, Mundle M, Ghosh S and Koley M. 2012. Effects of medical nutrition therapy on plasma lipoproteins of type II dyslipidemic patients: a short term pilot study. Asian J Pharm Clin Res, 5 (4): 207-211.
[2] Hossain MS, Ahmed M and Islam A. 2011. Hypolipidemic and hepatoprotective effects of different fractions of methanolic extract of Momordica charantia (linn.) in alloxan induced diabetic rats. Int J Pharma Sci Res, 2 (3): 601-607.
[3] Baynes HW. 2015. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab, 6: 541.
[4] Deguchi Y, Miyazaki K. 2010. Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract. Nutri Meta, 7 (9): 1-10.
[5] Tian L, Long S, Fu M, Liu Y, Xu Y and Jia L. 2011. Characteristics of high-density lipoprotein subclasses distribution for subjects with desirable total cholesterol levels. Hea Dise, 10 (64): 1-9.
[6] Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A and Vaziri ND. 2006. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in dietinduced metabolic syndrome. Metabolism, 55: 928-934.
[7] Dixit AK, Dey R, Suresh A, Chaudhuri S, Panda AK, Mitra A, et al. 2014. The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital. J Dia Met Diss, 13 (58): 1-5.
[8] Deng R. 2009. Food and food supplements with hypocholesterolemic effects. Rec Pat Food, Nutri Agri, 1: 15-24.
[9] Tosato M, Zamboni V, Ferrini A and Cesari M. 2007. The aging process and potential interventions to extend life expectancy. Clin Interv Aging, 2 (3): 401-412.
[10] Kumar V, Anwar F, Ahmed D, Verma A, Ahmed A, Damanhouri ZA, et al. 2014. Paederia foetida Linn. leaf extract: An antihyperlipidemic, antihyperglycaemic and antioxidant activity. BMC Comp Alt Med, 14 (1): 76.
[11] Farokhi F, Farkhad NK, Togmechi A and band KS. 2012. Preventive effects of Prangos ferulacea (L.) Lindle on liver damage of diabetic rats induced by alloxan. Avicenna J Phytomed, 2 (2): 63-71.
[12] Giannini EG, Testa R and Savarino V. 2005. Liver enzyme alteration: a guide for clinicians. CMAJ, 172 (3): 367-379.
[13] Oršolić N, Sirovina D, Končić MZ, Lacković G and Gregorović G. 2012. Effect of Croatian propolis on diabetic nephropathy and liver toxicity in mice. BMC Comp Alt Med, 12 (117): 1-12.
[14] Yamatani K, Marubashi S, Wakasugi K, Saito K, Sato N, Takahashai K, et al. 1994. Catecholamine-induced cAMP response in streptozotocin-induced diabetic rat liver. Tohoku J Exp Med, 173: 311-320.
[15] Zafar M, Naqvi S and Kaimkhani MA. 2009. Altered liver morphology and enzymes in streptozotocin induced diabetic rats. Int J Morphol, 27: 719-725.
[16] Pratt DS and Kaplan MM. 2009. Evaluation of abnormal liver enzyme results in asymptomatic patients. N Engl J Med, 342: 1266-1271.
[17] Ravikumar B, Gerrard J, Man CD, Firbank MJ, Lane A, English PT, et al. 2008. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes, 57 (9): 2288-2295.
[18] Etuk, EU. 2010. Animals models for studying diabetes mellitus. Agric Biol J N Am, 1 (2): 130-134.
[19] Claudino M, Ceolin DS, Alberti S, Cestari TM, Spadella CT, Rubira-Bullen IRF, et al. 2007. Alloxan-induced diabetes triggers the development of periodontal disease in rats. PLoS ONE, 2 (12): e1320.
[20] Sunday RM, Ilesanmi OR and Obuotor, EM. 2016. Anti-Diabetic effect of Anthocleista vogelii ethanolic root extract in alloxan-induced diabetic rats. Res J Med Plants, 10: 79-88.
[21] Saravanan R and Pari L. 2005. Antihyperlipidemic and antiperoxidative effect of Diasulin, a polyherbal formulation in alloxan induced hyperglycemic rats. BMC Comp Alt Med, 5 (14): 1-8.
[22] Szkudelski T. 2001. The mechanism of alloxan and streptozotocin action in β-cells of the rat pancreas. Physiol res, 50: 537-546.
[23] Safarzade A, and Talebi-Garakani E. 2014. Short term resistance training enhanced plasma apoA-I and FABP4 levels in Streptozotocin-induced diabetic rats. J Dia Meta Dis, 13 (41): 1-8.
[24] Manninen V, Tenkanen L, Koskinien P, , Huttunen JK, Mänttäri M, Heinonen OP, et al. 1992. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study: implications for treatment. Circulation, 85: 37-45.
[25] Sundaram R, Shanthi P, and Sachdanandam P. 2013. Effect of iridoidglucoside on plasma lipid profile, tissue fatty acid changes, inflammatory cytokines, and GLUT4 expression in skeletal muscle of streptozotocin-induced diabetic rats. Mol Cell Biochem, 380 (1–2): 43-55.
[26] Berredjem H, Reggami Y, Benlaifa M, Berredjem M, and Bouzerna N. 2015. antidiabetic and hypolipidemic potential of 3, 4-dihydroisoquinolin-2 (1H) - sulfonamide in alloxan induced diabetic rats. Int J Pharma, 11: 226-235.
[27] Uddin MS, Mamun AA, Hossain MS, Ashaduzzaman M, Noor MAA, Hossainet MS et al. 2016. Neuroprotective effect of Phyllanthus acidus L. on learning and memory impairment in scopolamine-induced animal model of dementia and oxidative stress: Natural wonder for regulating the development and progression of Alzheimer’s disease. Advances Alzheimer’s Dis, 5 (2), 53-72.
[28] Uddin MS, Mamun AA, Khanum S, Begum Y, and Alam MS. 2016. Analysis of in vitro antioxidant activity of Caryota urens L. leaves: A traditional natural remedy. J Coast Life Med, 4 (6): 483-489.
[29] Sujatha S, and Shalin JJ. 2012. Complementary therapeutic potential: a focus on polyherbal products for hyperglycemia. Asian J Sci Res, 5: 1-13.
[30] Mamum AA, Uddin MS, Wahid F, Iqbal MA and Rahman M. 2016. Neurodefensive effect of Olea europaea L. in alloxan-induced cognitive dysfunction and brain tissue oxidative stress in mice: incredible natural nootropic. J Neurol Neurosci, 7: S3.
[31] Uddin MS, Mamun AA, Hossain MS, Akter F, Iqbal MA and Asaduzzaman M. 2016. Exploring the effect of Phyllanthus emblica L. on cognitive performance, brain antioxidant markers and acetylcholinesterase activity in rats: promising natural gift for the mitigation of Alzheimer’s disease. Ann Neurosci, 4: 218-229.
[32] Hannan JMA, Ali L, Khaleque J, Akhter M, Flatt PR, and Abdel-Wahab YHA. 2012, Antihyperglycaemic activity of Asparagus racemosus roots is partly mediated by inhibition of carbohydrate digestion and absorption, and enhancement of cellular insulin action. British J of Nutri, 107: 1316-1317.
[33] Anonymus. Asparagus racemosus. USA: Available: http://en.wikipedia.org/wiki/Asparagus_racemosus. Accessed: 12 December, 2015.
[34] Sharma PC, Yelne MB, and Dennis TJ. 2000. Database on medicinal plants used in Ayurveda. Central Cou Res Ayur Sidd, 1: 418-430.
[35] Sairam KS, Priyambada NC, Goel RK. 2003. Gastroduodenal ulcer protective activity of Asparagus racemosus: An experimental, biochemical and histological study. J Ethnopharmacol, 86 (1): 1-10.
[36] Alok S, Jain SK, Verma A, Kumar M, Mahor A, and Sabharwal M. 2013. Plant profile, phytochemistry and pharmacology of Asparagus racemosus (Shatavari): A review. Asian Pac J Trop Dis, 3 (3): 242-251.
[37] Uddin MS, Asaduzzaman M, Mamun AA, Iqbal MA, Wahid F and Rony RK. 2016. Neuroprotective activity of Asparagus racemosus Linn. against ethanol-induced cognitive impairment and oxidative stress in rats brain: auspicious for controlling the risk of Alzheimer’s disease. J Alzheimers Dis Parkinsonism, 6(4): 245.
[38] Hannan JMA, Marenah L and Ali L. 2007. Insulin secretory actions of extracts of Asparagus racemosus Root in Perfused Pancreas, Isolated Islets and Clonal Pancreatic β-Cells. J Endo, 192, 159-168.
[39] Shao Y, Chin CK, Ho CT, Ma W, Garrison SA and Huang MT. 1996. Antitumour activity of the crude saponins obtained from asparagus. Cancer Let, 104: 31-36.
[40] Gang ZZ, Li LZ, and Xian LX. 1997. Study on the isolation, purification and antioxidation properties of polysaccharides from Spirulina maxima. Acta Bota Sinica, 39: 77-81.
[41] Zeng, N., Meng, X., and Zhang, Y. 1997. Studies on the antioxidative effect of constituents of Herba epimedii (ESPS). Zhongguo Zhon Zazhi, 22: 46-48.
[42] Liu J, Yeo HC, Doniger SJ, and Ames BN. 1997. Assay of aldehydes from lipid peroxidation: gas chromatography-mass spectrometry compared to thioabarbituric acid. Analy Bioche, 245 161-166.
[43] Liu SX. Chen Y, Zhou M, and Wan J. 1997. Protective effect of the polysaccharide kreskin on inhibition of lipo-polysaccharide-induced nitric oxide production in macrophages caused by oxidized low-density lipoprotein. Medi Sci Res, 25: 507-509.
[44] Mahammed NL, Jyothi G, Chary TN, Reddy CHV and Reddy GN. 2013. Antidiabetic and antihyperlipidamic activity of ethanolic extract of the leaf of Asperagus racemosus on streptozotocin induced diabetes rats. Int J Pharma Che Sci, 2 (2), 627-633.
[45] Organisation for Economic Cooperation and Development. 2002. OECD guidelines for the testing of chemicals: acute oral toxicity-acute toxic class method. Available: http://www.oecd-ilibrary.org/docserver/download/9742301e.pdf?ex. Accessed: 22 November 2015.
[46] Matsuura B, Kanno S, Minami H, Tsubouchi E, Iwai M, Matsui H, et al. 2004. Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver. J Gastroenterol. 39 (4): 339-45.
[47] National Research Council. (2011) Guide for the care and use of laboratory animals. National Academies Press, Washington D. C. (USA).
[48] Shah NA and Khan MR. (2014) Antidiabetic Effect of Sida cordata in Alloxan Induced Diabetic Rats. BioMed Res Int, 2014, 1-5.
[49] Sowers JR, Epstein M and Frohlich ED. Diabetes, hypertension, and cardiovascular disease an update. Hypertens, 37: 1053-1059.
[50] Dixit AK, Dey R, Suresh A, Chaudhuri S, Panda AK, Mitra A, et al. 2014. The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital. J Diabetes Meta Dis, 13 (58): 1-8.
[51] Elinasri HA and Ahmed AM. 2008. Patterns of lipid changes among type 2 diabetes patients in Sudan. Eastern Mediter Health J, 14: 2.
[52] Mooradian AD. 2009. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrin Metab, 5: 150-159.
[53] Ozder A. 2014. Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study. Lip Heal Dis, 13 (183) 1-6.
[54] Goldberg IJ. 2001. Diabetic dyslipidemia: Causes and consequences. J Clin Endo Metab, 8 (3): 965-971.
[55] Fernandes NPC, Lagishetty CV, Panda VS and Naik SR. 2007. An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC Comple Alt Med, 7 (29): 1-8.
[56] Koyaguru N, Kumar VH, Jamadar MG, Huligol SV, Nayak N, Yendigeri SM, et al. 2013. Antidiabetic and hepatoprotective activities of Tamarindus indica fruit pulp in alloxan induced diabetic rats. Int J Pharma-col and Clin Sci, 2: 33-40.
[57] Averill MM and Bornfeldt KE. 2009. Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. Curr Diab Rep, 9 (1): 18-25.
[58] Prince PSM, Menon VP and Gunasekaran G. 1998. Hypolipidaemic action of Tinospora cordifolia roots in alloxan diabetic rats. J Ethnopharmacol, 64 (1): 53-57.
[59] Valsa AK, Asha SK and Vijayalakshmi NR. 1998. Effect of catechin on intestinal lipid metabolism. Ind J Phy Pha, 42 (2): 286-90.
[60] Indradevi S, Ilavenil S, Kaleeswaran B, Srigopalram S and Ravikumar S. 2012. Ethanolic extract of Crinum asiaticum attenuates hyperglycemia-mediated oxidative stress and protects hepatocytes in alloxan induced experimental diabetic rats. J King Saud Uni-Sci, 24 (2): 171-177.
[61] Jr Brewer HB. 1999. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol, 83 (9B): 3F-12F.
[62] Daradka HM, Abas MM, Mohammad MAM and Jaffar MM. 2014. Antidiabetic effect of Artemisia absinthium extracts on alloxan-induced diabetic rats. Compa Cli Pat, 23 (6): 1733-1742.
[63] Tacer KF and Rozman D. 2011. Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids, 2011: 1-14.
[64] Niacin VH. 2009. A re-emerging pharmaceutical for the treatment of dyslipidaemia. Bri J Pharmaco, 158 (2): 429-441.
[65] Dheeba B, Kumar PS, Kannan M and Saravana K. 2012. Antidiabetic and antihyperlipidemic activities of Asparagus racemosus in alloxan induced diabetic rats. J Pharm Res, 5 (5): 2469-2472.
[66] Kumar RN, Sundaram R, Shanthi P and Sachdanandam P. 2013. Protective role of 20-OH ecdysone on lipid profile and tissue fatty acid changes in streptozotocin induced diabetic rats. Eur J Pharmaco, 698: 489-498.
[67] Noeman SA, Hamooda HE and Baalash AA. 2011. Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. Diabe Met Syn, 3 (17): 1-8.
[68] de Andrade KQ, Moura FA, dos Santos JM, de Araújo ORP, de Farias Santos JC and Goulart MOF. 2015. Oxidative stress and inflammation in hepatic diseases: therapeutic possibilities of N-Acetylcysteine. Int J Mol Sci, 16 (12): 30269-30308.
[69] Sepici-Dincel A, Açıkgöz Ş, Çevik C, Sengelen M and Yeşilada E. 2007. Effects of in vivo antioxidant enzyme activities of myrtle oil in normoglycaemic and alloxan diabetic rabbits. J Ethnopharmaco, 110 (3): 498-503.
[70] Bairwa NK, Sethiya NK and Mishra SH. 2010. Protective effect of stem bark of Ceiba pentandra Linn. against paracetamol-induced hepatotoxicity in rats. Pharmacog Res, 2 (1): 1-6.
[71] Navarro CM, Montilla PM, Martin A, Jimenez J and Utrilla PM. 1993. Free radicals scavenger and antihepatotoxic activity of Rosmarinus. Plant Med, 59: 312-314.
[72] Nkosi CZ, Opoku AR and Terblanche SE. 2005. Effect of pumpkin seed (Cucurbita pepo) protein isolate on the activity levels of certain plasma enzymes in CCl4-induced liver injury in low protein fed rats. Phytother Res, 19: 341-5.
[73] Rahimi P, Asgary S and Kabiri N. 2014. Hepatoprotective and hypolipidemic effects of carthamus tinctorius oil in alloxan-induced type 1 diabetic rats. J HerbMed Pharmacol, 3 (2): 107-111.
[74] Mythilypriya R, Shanthi P and Sachdanandam P. Oral acute and subacute toxicity studies with Kalpaamrutha, a modified indigenous prepraration on rats. J Health Science, 2007; 53 (4): 351-8.
[75] Lecker SH, Solomon V, Mitch WE and Goldberg AL. 1999. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr, 129 (1), 227S-237S.
[76] Edgerton DS, Basu R, Ramnanan CJ, Farmer TD, Neal D, Scott M, et al. 2010. Effect of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Ame J Phy-End Met, 298 (5): E1019-E1026.
[77] Sophia D and Manoharan S. 2007. Hypolipidemic activities of Ficus racemosa Linn. bark in alloxan induced diabetic rats. Afr J Trad CAM, 4 (3): 279-288.
Author Information
  • Department of Pharmacy, Southeast University, Dhaka, Bangladesh

  • Department of Pharmacy, Southeast University, Dhaka, Bangladesh

  • Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh

  • Department of Pharmacy, Southeast University, Dhaka, Bangladesh

  • Department of Pharmacy, Southeast University, Dhaka, Bangladesh

Cite This Article
  • APA Style

    Abdullah Al Mamun, Mahbubul Hossain, Ariful Islam, Sonia Zaman, Md. Sahab Uddin. (2016). Asparagus racemosus Linn. Potentiates the Hypolipidemic and Hepatoprotective Activity of Fenofibrate in Alloxan-Induced Diabetic Rats. Plant, 5(5-1), 1-12. https://doi.org/10.11648/j.plant.s.2017050501.11

    Copy | Download

    ACS Style

    Abdullah Al Mamun; Mahbubul Hossain; Ariful Islam; Sonia Zaman; Md. Sahab Uddin. Asparagus racemosus Linn. Potentiates the Hypolipidemic and Hepatoprotective Activity of Fenofibrate in Alloxan-Induced Diabetic Rats. Plant. 2016, 5(5-1), 1-12. doi: 10.11648/j.plant.s.2017050501.11

    Copy | Download

    AMA Style

    Abdullah Al Mamun, Mahbubul Hossain, Ariful Islam, Sonia Zaman, Md. Sahab Uddin. Asparagus racemosus Linn. Potentiates the Hypolipidemic and Hepatoprotective Activity of Fenofibrate in Alloxan-Induced Diabetic Rats. Plant. 2016;5(5-1):1-12. doi: 10.11648/j.plant.s.2017050501.11

    Copy | Download

  • @article{10.11648/j.plant.s.2017050501.11,
      author = {Abdullah Al Mamun and Mahbubul Hossain and Ariful Islam and Sonia Zaman and Md. Sahab Uddin},
      title = {Asparagus racemosus Linn. Potentiates the Hypolipidemic and Hepatoprotective Activity of Fenofibrate in Alloxan-Induced Diabetic Rats},
      journal = {Plant},
      volume = {5},
      number = {5-1},
      pages = {1-12},
      doi = {10.11648/j.plant.s.2017050501.11},
      url = {https://doi.org/10.11648/j.plant.s.2017050501.11},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.plant.s.2017050501.11},
      abstract = {Diabetes mellitus is strongly connected with changes in lipid profile and also can cause damage of several organs like liver over a long period of time. The purpose of this study was designed to evaluate the hypolipidemic and hepatoprotective effects of ethanolic root extracts of Asparagus racemosus (EEAR) Linn. alone and in combination with a lipid lowering agent (fenofibrate) in alloxan-induced diabetic rats. Diabetes was induced in male Wister albino rats by the administration of single intra-peritoneal injection of alloxan monohydrate (120 mg/kg b.w.). Two different doses of EEAR (200 and 400 mg/kg b.w.) alone, fenofibrate (30 mg/kg b.w.) and a combination of EEAR (200 mg/kg b.w.) with fenofibrate (30 mg/kg b.w.) were administered orally for the period of 14 days. After the treatment period, hypolipidemic and hepatoprotective effects were determined by examining serum biochemical markers including total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), very low density lipoprotein (VLDL), high density lipoprotein (HDL), serum glutamate oxaloacetate transaminases (SGOT), serum glutamate pyruvate transaminases (SGPT) and total protein (TP) with the aid of commercially available kits. The survival rate, body weight and organ weight were also measured. The ingestion of EEAR considerably (p th and 14th day as compared to that of disease control and fenofibrate treated rats. In case of organs weight, the weight of the liver and weight of the pancreas were significantly (p < 0.001; p < 0.05, p < 0.01, p < 0.001) decreased in the rats treated with highest dose of EEAR (Alx+ EEAR 400) and combination therapy when compared to the disease control and fenofibrate treated rats. The current study demonstrates that combination therapy of EEAR and fenofibrate was more effective than that of monotherapy in controlling diabetes mellitus associated with cardiovascular diseases and hepatic dysfunction in alloxan-induced diabetic rats.},
     year = {2016}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Asparagus racemosus Linn. Potentiates the Hypolipidemic and Hepatoprotective Activity of Fenofibrate in Alloxan-Induced Diabetic Rats
    AU  - Abdullah Al Mamun
    AU  - Mahbubul Hossain
    AU  - Ariful Islam
    AU  - Sonia Zaman
    AU  - Md. Sahab Uddin
    Y1  - 2016/10/18
    PY  - 2016
    N1  - https://doi.org/10.11648/j.plant.s.2017050501.11
    DO  - 10.11648/j.plant.s.2017050501.11
    T2  - Plant
    JF  - Plant
    JO  - Plant
    SP  - 1
    EP  - 12
    PB  - Science Publishing Group
    SN  - 2331-0677
    UR  - https://doi.org/10.11648/j.plant.s.2017050501.11
    AB  - Diabetes mellitus is strongly connected with changes in lipid profile and also can cause damage of several organs like liver over a long period of time. The purpose of this study was designed to evaluate the hypolipidemic and hepatoprotective effects of ethanolic root extracts of Asparagus racemosus (EEAR) Linn. alone and in combination with a lipid lowering agent (fenofibrate) in alloxan-induced diabetic rats. Diabetes was induced in male Wister albino rats by the administration of single intra-peritoneal injection of alloxan monohydrate (120 mg/kg b.w.). Two different doses of EEAR (200 and 400 mg/kg b.w.) alone, fenofibrate (30 mg/kg b.w.) and a combination of EEAR (200 mg/kg b.w.) with fenofibrate (30 mg/kg b.w.) were administered orally for the period of 14 days. After the treatment period, hypolipidemic and hepatoprotective effects were determined by examining serum biochemical markers including total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), very low density lipoprotein (VLDL), high density lipoprotein (HDL), serum glutamate oxaloacetate transaminases (SGOT), serum glutamate pyruvate transaminases (SGPT) and total protein (TP) with the aid of commercially available kits. The survival rate, body weight and organ weight were also measured. The ingestion of EEAR considerably (p th and 14th day as compared to that of disease control and fenofibrate treated rats. In case of organs weight, the weight of the liver and weight of the pancreas were significantly (p < 0.001; p < 0.05, p < 0.01, p < 0.001) decreased in the rats treated with highest dose of EEAR (Alx+ EEAR 400) and combination therapy when compared to the disease control and fenofibrate treated rats. The current study demonstrates that combination therapy of EEAR and fenofibrate was more effective than that of monotherapy in controlling diabetes mellitus associated with cardiovascular diseases and hepatic dysfunction in alloxan-induced diabetic rats.
    VL  - 5
    IS  - 5-1
    ER  - 

    Copy | Download

  • Sections